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Abstract 
Pennicillipyrone A and B are two novel meroterpenoids isolated from the marine-derived 
fungus Penicilliump sp. Although a preliminary toxicity studies demonstrated the 
bioactivity of penicillipyrone A to be far superior to that of its congener penicillipyrone B, 
we were intrigued by its structure.  Moreover, it appeared as though one could design an 
efficient total synthesis based on chemistry that was familiar to our laboratory. 
The purpose of this project was the study of a new synthesis of Pennicillipyrone B by way 
of a doubley-biomimetic approach. The intended approach proceeds through a polyene 
cascade reaction terminated by a nucleophilic pyrone - a reaction not yet known in the 
literature for the construction of this type of scaffold. 
During the course of this study we have learned about the unanticipated reactivity of C2 
substituted keto-dioxinones with regard to self-condensation.  In addition, four new 
compounds were synthesized and two synthetic routes to the target molecule are presented. 
 
 
Riassunto 
Pennicillipyrone A e B sono due nuovi meroterpenoidi isolati dal fungo marino 
Penicilliump sp. Sebbene studi preliminari di tossicità hanno dimostrato l’attività biologica 
del penicillipyrone A essere di gran lunga superiore a quella del suo congenere 
penicillipyrone B, siamo stati colpiti dalla sua struttura. Inoltre, è sembrato che si potesse 
progettare un efficace sintesi basata sulla chimica già familiare al nostro laboratorio. 
Lo scopo di questo progetto è lo studio di una nuova sintesi del Pennicillipyrone B 
attraverso un approccio doubley-biomimetico. L’intento era sviluppare una reazione non 
ancora nota in letteratura basata sulla ciclizzazione di polieni con il metodo di Cascade 
avendo per terminale un gruppo pirone. 
Nel corso di questo studio abbiamo scoperto la reattività del sostituente in posizione C2 
del cheto-diossinone per quanto riguarda l’auto-condensazione. Inoltre, sono stati 
sintetizzati quattro nuovi composti e sono mostrate due vie sintetiche per la molecola 
bersaglio. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of Abbreviations 
 
α   alpha 
β  beta 
μL micro litres  
ºC celcius degree 
  
Ac  acetyl 
Ac2O  acetic anyhydride 
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bp boiling point 
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d   doublet 
dd   doublet of doublet 
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DCC N,N'-Dicyclohexylcarbodiimide 
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1.1 Introduction.  
 
The natural products assembled by nature are a rich source of compounds with potential 
therapeutic application.  In fact, natural products, or more often their derivatives, have been 
exploited for the use of treating human disease for many centuries.  The oldest known 
record dates back to 2400 BC in China where plants were exploited for medicinal purposes. 
In more recent times the use of modern extraction and screening methods combined with 
chemical synthesis provide a powerful arsenal for the discovery of new drugs.  Of the 
1000+ drugs approved for market between 1981 and 2010, approximately 50% were 
natural product derived.1 
 
By definition, natural products constitute any type of chemical compound produced by a 
living organism.  In the context of medicinal chemistry, these compounds are most often 
secondary metabolites and are thus not directly involved in growth and development.2 
 
There are two reasons why secondary metabolites of organisms are such a unique and 
important source of drug prospects.  Firstly, one must understand the role they play in 
nature.  These compound are often used in a species’ defense, survival, or regulatory 
processes. The second important reason has to do with the molecular homology present 
between different species. 
 
To perform the task for which a molecule has been designed, Nature has encoded very 
specific information into its chemical structure.  This information, for example, can cause 
an interaction to take place between a specific protein receptor cite to trigger a response.  
The molecular homology between different species permits this interaction to be 
transferred to another organism.3 Thus we may “borrow” the necessary code responsible 
for a specific interaction between a particular natural product and a protein in an organism.  
Through the power of chemical synthesis we may perform the necessary structural editing 
of a natural product to fine tune the interaction and/or other chemical properties needed for 
drug ability in humans.  
 
One particular class of natural product that could have a potential therapeutic application 
are the meroterpenoids.  Penicillipyrones A and B are two novel meroterpenoids, isolated 
from the marine derived fungus Penicillium sp.4 Compound A exhibited significant 
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induction of quinone reductase (QR) which is a representative detoxification enzyme, and 
is known to play an important anticancer role through the reduction of electrophilic 
quinones.5,6 Therefore, the significant induction of QR by penicillipyrone A may be 
suggestive of a potential role in cancer prevention. 
 
 
 
Figure 1. Pennicillipyrone A (1A) and B (1B) 
 
Although a preliminary toxicity studies demonstrated the bioactivity of penicillipyrone A 
to be far superior to that of its congener penicillipyrone B, we were intrigued by its 
structure.  Moreover, it appeared as though one could design an efficient total synthesis 
based on chemistry that was familiar to our laboratory.7 
 
To the best of our knowledge at the outset of this work were no literature examples of 
polyene cascade reactions terminated by a nucleophilic pyrone moiety. It was thought that 
the knowledge gained from this work could be later applied to a synthetic study of 
penicillipyrone A.  Thus, the goal of this thesis was to study the synthesis of penicillipyone 
B by way of a doubley-biomimetic approach (Figure 2).   
 
 
 
 
Figure 2. Analysis of Penicillipyrones B (1B) 
 
 4   
 
We envisoned that an appropriately substituted keto-dioxinone derivative would serve as 
an ideal synthetic precursor to the natural product scaffold (Figure 2). An intramolecular 
condensation of the keto-dioxinone moiety would give rise to -pyrone moiety. This 
intermediate could then undergo a Lewis acid catalyzed Johnson-Type cyclization,8 which 
would furnish the terpenoid framework. Following the principles set forth by Stork and 
Eschenmoser,9,10 the geometrically defined olefins in substrate (2B) and the well-ordered 
nature of the transition state would furnish with the desired trans-anti-trans relative 
stereochemistry at each ring junction in Penicicilliprone B (Figure 3). 
 
 
 
Figure 3. Johnson-Type Cylization  
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1.2 Results and Discussion. 
 
Our first synthetic route utilized a cross coupling reaction,11 between two key building 
blocks – the known iodo-dioxinone (5) and the farnesyl derivative (6) (Figure 4).  After 
pyrone formation and protecting group removal, conversion of the terminal diol into the 
epoxide would give the Johnson cyclization precursor.  
 
 
 
 
Figure 4. Retrosynthetic Analysis of Penicillipyrones B via Dioxinone 
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1.2.1 Synthesis of Farnesyl Bromide derivative (6). 
 
The chiral alkyl halide (6) was obtained in 6 steps from commercially available farnesol. 
Acylation of farnesol (7) with acetic anhydride and DMAP gave the corresponding acetate 
(8).12 The Sharpless dihydroxylation was used to prepare the 10,11-diol (9) in an 
enantioselective fashion. This product was protected as the corresponding acetonide (10) 
with Dimethoxypropane and a catalytic amount of CSA.  After hydrolysis of the acetate 
(10→11) the primary alcohol was converted to the corresponding bromide (6) in two 
additional steps.13 
 
 
Scheme 1. Synthesis of Farnesyl Bromide Derivative 
 
1.2.2 Synthesis of Iodo-Dioxinone (5). 
 
Iodo-dioxinone (5) was prepared following a literature description by treatment of 
Dioxinone with N-Iodosuccinimide (NIS) in acetic acid.14 
 
 
Scheme 2. Synthesis of Iodo-Dioxinone  
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1.2.3 Cross coupling reaction. 
  
 
Scheme 3. Cross coupling reaction 
 
With building blocks 5 and 6.3 in hand we decided to investigate the requisite cross 
coupling reaction. Although the cross coupling reaction among allyl bromide and 
dioxinone 5 is known, at the time of our study there were no literature examples of more 
complex allylic substrates.   
 
Before screening the reaction with alkyl bromide (6.3) we decided to investigate the 
conditions with a model compound. Treatment of prenyl bromide (6.1) with the cuprate 
prepared from iodo dioxinone and isopropyl magnesium bromide gave the desired product 
in fairly modest yield (44%).  We speculated that a competitive coupling event between 
isopropyl magnesium bromide and the allyl halide was taking place.  After switching the 
model compound to the less volatile geranyl bromide we did indeed see compound (13.4) 
as a byproduct in the reaction conditions.  Ultimately, we managed to improve the yield of 
the desired coupling product by increasing the number of equivalents of iodo-dioxinone 
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from 1 to 1.5 with respect to the alkyl bromide derivative. We saw an increase in yield 
from 30 to 77 % in the geranyl compound (13.2). Interestingly when we applied our 
optimized reaction conditions to the real system (6.3), we could only obtain the coupled 
product (13.3) in 43% yield.  Increasing the number of sacrificial equivalents of iodo-
dioxinone (5) did not offer any improvement. 
We speculate that chelation of the copper complex to the oxygens of the acetonide 
protecting group may inhibit coupling. 
 
P 5 R n. eq. Of i-PrMgBr n. eq. CuCN * 2 LiCl n. eq. Of R n. eq. Of Iodo-Dioxinone Yield % 
13.1 6.1 1,1 1 1,2 1 44 
13.2 6.2 1,1 1 1,2 1 38 
13.2 6.2 1,1 1 1 1,5 77 
13.3 6.3 1,1 1 1 1,5 43 
 
Table 1. Condition and result of Cross Coupling reaction 
 
1.2.4 Claisen reaction Keto-Dioxinone Farnesyl derivative. 
 
Keto-dioxinone (4) was synthesized by acylation of the enolate from dioxinone (13) with 
acetyl chloride in THF at -78 °C.15 
 
 
Scheme 4. Claisen reaction 
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Product S.M. n. eq. Of LiN(SiMe3)2 n. eq. AcCl n. eq. 10 Yield % 
4.1 13.1 1 1 1 36 
4.2 13.2 1 1 1 35 
4.3 13.3 1 1 1 33 
 
Table 2. Condition and result of Claisen reaction  
 
1.3 Unsuccessful Attempt at Pyrone derivative. 
 
With the desired cross-coupled product in hand, our next task was to construct the pyrone.  
For this purpose we had two unique options: one could effect intramolecular cyclization to 
form the pyrone via base catalysis or through ketene trapping. There are a number of 
examples in the literature that employ these methods in total synthesis.16  
 
 
 
Figure 5. Ketene trapping  
 
Despite having two possible options to build the pyrone moiety we were ultimately left 
disappointed as neither method proved effective. When keto-dioxinone 14 was heated to a 
temperature that would presumably generate ketene 15 via retro-Diels Alder reaction, we 
only observed substrate decomposition.  Addition of DBU did not offer any improvement.  
 
 
 
 
 
 
Treatment of keto-dioxinone (14) with NaOMe,17 also led to substrate decomposition; 
prolonged reaction times gave a mixture of starting material and dioxinone, presumably 
via a retro Claisen reaction.   
 
 10   
 
 
 
 
Scheme 5. Keto-Dioxinone Methanolysis 
 
While we were left disappointed with this result, we were not entirely surprised.  After an 
extensive literature search, we found that there are no examples of intramolecular 
cyclization of keto-dioxinones to form pyrones with extended chains at the C-2 position. 
It is possible that a substituent at the C2 position prevents the reactive ketene intermediate 
from adopting a conformation, which would allow intramolecular attack.  Alternatively 
ketene formation may be entirely retarded by the C2 substituent.  To fully understand the 
reasons why this reaction failed requires additional experiments and may be a future 
investigation in the Barrett laboratories. 
 
 
 
Scheme 6. Intramolecular Cyclization reaction 
 
Staring Material Reaction conditions Result 
4.1 Toluene, Reflux s.m. recovered 
4.1 Methanol, 2 eq. MeONa, 0°C s.m. recovered 
4.2 Methanol, 2 eq. MeONa, 0°C to 45°C S.m. and retro Claisen reaction product 
4.2 Benzene, 1 eq. DBU, 83°C complex mixture of unidentifiable products 
14 Methanol, 2 eq. MeONa, 0°C s.m. recovered 
14 Toluene, Reflux % yield product 
 
Table 3.Condition and result of Intramolecular reaction
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2.1 Introduction 
 
To bypass this hurdle, we redesigned our synthetic strategy. We intended to solve the 
problem of pyrone construction in our second approach by using the diketo ester 17 rather 
than a keto-dioxinone.  The chemoselective alkylation of diketoesters at the C-2 position 
via the copper acetate complex has been described by Cervello et al.18 In addition, the 
literature did contain examples of C-2 substituted pyrones constructed via condensation of 
keto esters. 
 
 
 
 
Figure 6. Retrosynthetic Analysis of Penicillipyrones B via Pyrone 
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2.2 Result and Discussion  
2.2.1 Synthesis of Pyrone derivative  
 
Triacetic acid lactone (17) was synthesized from keto-dioxinone (14), a compound we had 
available in gram quantities in our laboratory. After acylation of the pyrone (16→20) we 
obtained the α-β-diketoester (17) by treatment with magnesium powder in methanol. 
Reaction of the diketoester (17) with copper acetate in water/methanol afforded the 
complex (21) (scheme 7), which exhibits a peak at 1734 cm-1 in the infrared spectrum. 
 
 
Scheme 7. Synthesis of Cupper Complex 
 
2.2.2 Synthesis of Epoxyfarnesyl bromide  
 
Racemic epoxy farnesyl acetate (24) was prepared according to a literature procedure19 
and was available in gram quantities in our laboratory. After deprotection of the ester (22 
→23) bromide 24 was prepared in two steps from alcohol 23.  
 
 
 
Scheme 8. Synthesis of Epoxyfarnesyl bromide 
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2.3 Attempt coupling to Pyrone derivative  
 
At last we were set up to couple epoxy bromide 24 with copper complex 21.  In the event, 
treatment of 21 with sodium hydride in THF followed by primary alkylhalide 24 and 
subsequent hydrolysis gave a mixture of products.  Although it appeared as though the 
desired keto ester 19 was present in the crude reaction mixture, it was impossible to isolate.  
Due to time constraints the continuation of work on this project ceased at this point.  
  
 
Scheme 9. Synthesis of Ketoester pyrone derivative 
 
2.4 Conclusions and perspectives 
 
In conclusion we have developed a straightforward synthesis to compound 4.2 and 4.3.  
These compounds are key building blocks for further studies to understand the influence 
of a side chain on the reactivity C2 substituted keto-dioxinones with regard to pyrone 
synthesis. 
To move forward we plan the construction of the pyrone via the last method herein 
described. 
Once we successfully obtain the beta keto ester with the farnesyl epoxy side chain in 
position C2 (25), we will investigate the cascade reaction, using different Lewis acids, 
solvents and reaction conditions. The stereochemistry obtained in the ring system of the 
product, after this key reaction, will be established by means of spectroscopic analyses 
such as 1H NMR (e.g. NoE and 2D correlation spectroscopy) and by comparison to the 
known compound. 
 
 
 15   
 
 
Scheme 10. Further studies: the cascade reaction toward compound 1B 
 
This study is ongoing and still under investigation in the Barrett Laboratories. 
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3.1 Experimental Section 
 
General Information 
 
All air- and moisture-sensitive reactions were performed under argon in oven-dried or 
flame-dried glassware. Unless stated otherwise, commercially available reagents were 
used as supplied or distilled by short-path distillation. Tetrahydrofuran (THF) was distilled 
under argon gas. Methanol (MeOH) was distilled from metallic sodium under nitrogen gas. 
 
All experiments were monitored by thin layer chromatography (TLC) performed on 
Whatman precoated PE SIL G/UV 250 μm layer polyester-supported flexible plates. Spots 
were visualized by exposure to ultraviolet (UV) light (254 nm) or by staining with 10% 
solution of phosphomolybdenic acid (PMA) in ethanol, or vanilline, and heat as developing 
agents. 
 
Flash chromatography was carried out with Fisher brand silica gel (170-400 mesh). 
Infrared spectra were recorded with a Perkin-Elmer 1600 Series FT-IR instrument. Nuclear 
magnetic resonance (NMR) spectra were recorded with a Varian Inova-500 (500 MHz for 
1H and 126 MHz for 13C), Varian Inova-400 (400 MHz for 1H and 101 MHz for 13C) 
spectrometer. Chemical shifts for proton NMR spectra are reported in parts per million 
(ppm) relative to the singlet at 7.26 ppm for chloroform-d. Peak multiplicities are 
abbreviated: singlet, s; doublet, d; triplet, t; multiplet; m.  
 
Coupling constants are reported in hertz (Hz). Chemical shifts for carbon NMR spectra are 
reported in ppm with the center line of the triplet for chloroform-d set at 77.00 ppm. High-
resolution mass spectra were obtained on a Micromass Q-Tof Ultima spectrometer by the 
Mass Spectrometry Laboratory at the Imperial College Universtity. 
 
 
 
 
 
 
 
 
 
 
17 
 
3.2 Experimental Procedure/Characterization 
 
 
(2E,6E)-Farnesyl Acetate (8).  Acetic anyhydride (44.3 mL, 469 mmol, 3 eq.) was added 
dropwise to a solution of (2E,6E)-farnesol (34.7 g, 156 mmol, 1 eq.), 4-DMAP (9.56 g, 
78.2 mmol, 0.5 eq.), and Et3N (110 mL, 782 mmol, 5 eq.) in CH2Cl2 (500 mL) at 0 °C. 
After stirring for 60 min at 0 °C, the reaction contents were quenched by the addition of 
water, and the crude product was extracted with CH2Cl2 (3 × 200mL). The combined 
organic solution was washed with 1 M HCl (100 mL; back-extracted with 25 mL CH2Cl2), 
saturated aqueous NaHCO3 (100mL; back-extracted with 25 mL CH2Cl2), and brine (100 
mL; back-extracted with 25 mL CH2Cl2). The combined organic solution was dried 
(MgSO4), filtered, and concentrated. Chromatography through a silica gel plug (20 × 50 
mm) with Pentene:EtOAc (15:1 to 5:1) afforded 8 (40.4 g, 98% yield) as a light yellow 
viscous oil: Rf = 0.53 (silica gel, Pentene:EtOAc, 5:1). 20 
1H NMR (400 MHz, CDCl3) δ 5.42 – 5.33 (tq, J = 7.2, 1.4 Hz, 1H), 5.18 – 5.06 (m, 2H), 
4.66 – 4.56 (d, J = 7.1 Hz, 2H), 2.24 – 1.92 (m, 11H), 1.75 – 1.69 (dd, J = 10.7, 1.3 Hz, 
6H), 1.64 – 1.60 (d, J = 1.7 Hz, 6H). 
 
 
 
(R,2E,6E)-10,11-Dihydroxy-3,7,11-trimethyldodeca-2,6-dienyl Acetate (9). To a stirred 
suspension of AD-mix-β (21.6 g) and MsNH2 (2.76 g, 29.1 mmol, 1.05 eq.) in t-
BuOH/water (900 mL, 1:1) was added a solution of farnesyl acetate 8 (7.30 g, 27.7 mmol) 
in t-BuOH/water (50 mL, 1:1) at 0 °C. The reaction mixture was stirred at that temperature 
for 17 h before it was quenched with saturated aq. NaHCO3 (80 mL). The resulting mixture 
was extracted with EtOAc (3 × 150 mL), and the combined organic solution was washed 
with brine (100 mL) and dried over anhydrous MgSO4. After filtration and removal of the 
solvent under vacuum, the residue was purified by flash column chromatography with 
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EtOAc/Pentene (1:2) to give diol 9 (1.53 g, 18 %) as a pale yellow oil: Rf = 0.34 (silica, 
EtOAc:Pentene 1:1). 21 
 
1H NMR (400 MHz, CDCl3) δ 5.35 – 5.24 (tq, J = 6.8, 1.4 Hz, 1H), 5.18 – 5.07 (m, 1H), 
4.60 – 4.50 (d, J = 7.1 Hz, 2H), 3.35 – 3.23 (d, J = 10.3 Hz, 1H), 2.58 – 2.50 (d, J = 4.1 
Hz, 1H), 2.44 – 2.37 (s, 1H), 2.32 – 1.93 (m, 10H), 1.73 – 1.62 (m, 6H), 1.61 – 1.47 (m, 
1H), 1.18 – 1.09 (d, J = 16.7 Hz, 6H) 
 
 
Acetonide (10). To a solution of the known chiral diol 9 (206 mg, 0.67 mmol) in 3.0 mL 
of dichloromethane were added (±)-10-camphorsulfonic acid (8.0 mg, 33.5 μmol, 0.05 eq.) 
and 2,2-dimethoxypropane (0.25 mL, 2.01 mmol, 3 eq.) at 0 °C under a argon atmosphere, 
and the mixture was stirred at room temperature for 1 h. A saturated aqueous solution of 
sodium bicarbonate (5 mL) was added to the solution, and the aqueous layer was extracted 
with dichloromethane (5 mL × 3). The organic layer was dried over anhydrous magnesium 
sulfate and concentrated in vacuo. The residue was subjected to column chromatography 
(Pentane/ethyl acetate = 10:1) on 5 g of silica gel to yield acetonide 10 (186 mg, 80% yield) 
as a colorless oil: Rf = 0.63 (hexane/ethyl acetate = 70:30). 
1H NMR (400 MHz, CDCl3) δ 4.65 – 4.54 (d, J = 7.0 Hz, 3H), 3.69 – 3.61 (dd, J = 9.2, 3.5 
Hz, 1H), 2.37 – 1.93 (m, 10H), 1.78 – 1.56 (d, J = 1.3 Hz, 3H), 1.51 – 1.37 (s, 6H), 1.37 – 
1.27 (d, J = 2.8 Hz, 3H), 1.28 – 1.20 (s, 3H), 1.20 – 1.02 (d, J = 6.0 Hz, 3H) 
 
 
 
Alcohol (11). To a solution of acetonide 10 (186 mg, 0.55 mmol, 1 eq.) in 3.30 mL of 
methanol was added potassium carbonate (570 mg, 4.12 mmol, 7.5 eq), and the mixture 
was stirred at room temperature for 15 min. Water (20 mL) was added and the aqueous 
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solution was extracted with dichloromethane (20 mL × 3). The combined organic solution 
was washed with brine, dried over anhydrous magnesium sulfate, and concentrated under 
reduced pressure. The residue was subjected to column chromatography (Pentene/ethyl 
acetate = 5:1 to 1:1) on 5 g of silica gel to furnish alcohol 11 (140 mg, 65% yield) as a 
colorless oil: Rf = 0.31 (hexane/ethyl acetate = 70:30). 
 
1H NMR (400 MHz, CDCl3) δ 5.50 – 5.36 (m, 1H), 5.22 – 5.12 (tt, J = 6.6, 1.6 Hz, 1H), 
4.21 – 4.12 (t, J = 5.9 Hz, 2H), 3.70 – 3.61 (dd, J = 9.2, 3.5 Hz, 1H), 2.33 – 1.92 (m, 8H), 
1.76 – 1.66 (m, 4H), 1.66 – 1.58 (m, 3H), 1.45 – 1.41 (d, J = 2.7 Hz, 3H), 1.35 – 1.29 (s, 
3H), 1.29 – 1.21 (s, 3H), 1.17 – 1.06 (m, 3H) 
 
 
 
(10R)-10,11-Isopropylidenedioxy-10,11-dihydrofarnesyl bromide (6). To a solution of 
the allylic alcohol 11 (140 mg, 0.48 mmol, 1 eq.) and Et3N (0.16 mL, 1.86 mmol, 3.8 eq.) 
in 3 mL of dry THF was added MsCl (96 µL, 1.24 mmol, 2.5 eq.) at -45 °C under Ar. After 
the mixture was stirred at this temperature for 45 min and then at 0 °C for 30 min, a solution 
of LiBr (2M in THF, 1.2 mL, 2.4 mmol, 5 eq.) was added and stirring was continued at 0 
°C for 1 h. The reaction mixture was the poured into a mixture of pentene (15 mL) and ice-
cooled NaHCO3 (15 mL). The organic solution was separated and the aqueous layer was 
extracted twice with 15 mL of pentene. The combined organic phase was washed with 
brine and dried (MgSO4). After removal of the solvent, 54.6 mg (88 %) of allylic bromide 
6 was obtained as a colorless oil, which is pure enough for the following reaction. 22 
 
1H NMR (400 MHz, CDCl3) δ 5.55 – 5.42 (tt, J = 8.1, 1.2 Hz, 1H), 5.36 – 5.21 (m, 1H), 
3.82 – 3.72 (m, 3H), 2.57 – 1.68 (m, 8H), 1.66 – 1.61 (s, 3H), 1.61 – 1.58 (s, 3H), 1.53 – 
1.48 (s, 3H), 1.48 – 1.46 (s, 3H), 1.30 – 1.24 (s, 3H), 1.24 – 1.18 (s, 3H) 
 
 
 
20 
 
 
 
5-iodo-1,3-dioxin-4-one (5). A solution of 2,2,6-trimethyl-1,3-dioxin-4-one 12 (142 mg; 
1 mmol, 1 eq.) and N-iodosuccinimide (NIS) (310 mg; 1.3 mmol, 1.3 eq.) in acetic acid 
(2.5 mL) was stirred for 19 h at room temperature in the dark. The reaction mixture was 
diluted with water (30 mL) and extracted with ethyl acetate (3 x 30 mL). The organic 
solution was washed with water (20 mL) and dried over MgSO4. The residue obtained after 
evaporation of the solvent was chromatographed on silica gel (Pentene–AcOEt 10:1) to 
give the 2,2,6-trimethyl-5-iodo-1,3-dioxin-4-one 5 as pale yellow prisms (118 mg; 41%). 
23 
1H NMR (400 MHz, CDCl3) δ 2.34 – 2.27 (s, 3H), 1.74 – 1.66 (s, 6H) 
 
 
 
5-Prenyl-2,2,6-trimethyl-[1,3]dioxin-4-one (13.1). A solution of i-PrMgBr (1.74 mL, 1.1 
mmol, 1.1 eq.) in THF (0.63 M) was added dropwise over 5 min to a stirred solution of the 
5-iodo-1,3-dioxin-4-one  5 (268 mg, 1.0 mmol, 1.0 eq.) in THF (1.35 mL) at -30 °C under 
Argon. After 1 h a solution of Copper (I) cyanide di (Lithium Chloride) complex (0.18 mL, 
1.1 mmol, 1.1 eq.) was added dropwise. The resulting solution was then stirred for 30 min 
and Prenyl Bromide (0.15 mL, 1.2 mmol, 1.2 eq.) was added. The reaction mixture was 
allowed to warm to room temperature, brine was added and the reaction mixture was 
worked up as usual. The crude residue was purified by column chromatography on silica 
to give 13.1 (93.6 mg, 44 %) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ 5.13 – 4.98 (tp, J = 4.6, 1.8 Hz, 1H), 2.99 – 2.90 (d, J = 6.8 
Hz, 2H), 2.00 – 1.92 (s, 3H), 1.72 – 1.67 (m, 6H), 1.67 – 1.60 (s, 6H)  
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5-Geranyl-2,2,6-trimethyl-[1,3]dioxin-4-one (13.2). A solution of i-PrMgBr (2.90 mL, 
1.65 mmol, 1.1 eq.) in THF (0.56 M) was added dropwise over 5 min to a stirred solution 
of the 5-iodo-1,3-dioxin-4-one (5) (402 mg, 1.5 mmol, 1.5 eq) in THF (1.35 mL) at -30 °C 
under Argon. After 1 h a solution of Copper(I) cyanide di(Lithium Chloride) complex (0.26 
mL, 1.5 mmol, 1.1 eq.) was added dropwise. The resulting solution was then stirred for 30 
min and Geranyl Bromide (0.38 mL, 1.95 mmol, 1.0 eq.) was added. The reaction mixture 
was allowed to warm to room temperature, brine was added and the reaction mixture was 
worked up as usual. The crude residue was purified by column chromatography on silica 
to give 13.2 (281 mg, 77 %) as a colorless oil. 
 
1H NMR (400 MHz, CDCl3) δ 5.11 – 4.94 (m, 2H), 3.05 – 2.85 (d, J = 6.8 Hz, 2H), 2.16 – 
1.91 (m, 7H), 1.70 – 1.63 (m, 12H), 1.60 – 1.58 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
163.4, 162.2, 135.8, 131.4, 124.1, 121.5, 105.0, 104.7, 39.6, 26.5, 25.7, 25.0, 23.7, 17.7, 
17.4, 16.1. IR (film): ν = 2973, 2919, 2852, 1721, 1645, 1390 cm-1 HRMS [ES+] calc for 
C17H27O3 [M+H]
+ 279.1960, found 279.1958. 
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5-[10,11-Isopropylidenedioxy-10,11-dihydrofarnesyl]-2,2,6-trimethyl-[1,3]dioxin-4-one 
(13.3). A solution of i-PrMgBr (0.76 mL, 0.36 mmol, 1.1 eq.) in THF (0.43 M) was added 
dropwise over 5 min to a stirred solution of the 5-iodo-1,3-dioxin-4-one (5) (101 mg, 0.38 
mmol, 1.5 eq) in THF (1.35 mL) at -30 °C under Argon. After 1 h a solution of Copper(I) 
cyanide di(Lithium Chloride) complex (62 µL, 0.36 mmol, 1.1 eq.) was added dropwise. 
The resulting solution was then stirred for 30 min and Farnesyl Bromide (7) (100 mg, 0.27 
mmol, 1.0 eq.) was added. The reaction mixture was allowed to warm to room temperature, 
brine was added and the reaction mixture was worked up as usual. The crude residue was 
purified by column chromatography on silica to give 13.3 (50.2 mg, 43 %) as a colorless 
oil. 
 
1H NMR (400 MHz, CDCl3) δ 5.19 – 5.01 (dt, J = 25.3, 6.9 Hz, 2H), 3.73 – 3.58 (dd, J = 
9.3, 3.5 Hz, 1H), 3.02 – 2.92 (d, J = 6.8 Hz, 2H), 2.25 – 1.98 (m, 8H), 1.98 – 1.94 (s, 3H), 
1.71 – 1.67 (s, 3H), 1.66 – 1.63 (s, 6H), 1.62 – 1.59 (s, 3H), 1.44 – 1.41 (s, 3H), 1.34 – 
1.30 (s, 3H), 1.27 – 1.21 (s, 3H), 1.11 – 1.07 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 163.4, 
162.2, 135.8, 134.4, 124.5, 121.5, 106.4, 104.9, 104.8, 82.8, 80.1, 39.6, 36.7, 29.7, 28.6, 
27.7, 26.9, 26.6, 26.1, 25.0, 23.7, 22.9, 17.4, 16.2, 16.00. IR (film): ν = 2983, 2920, 2850, 
1727, 1646, 1236 cm-1 HRMS [ES+] calc for C25H40O5Na [M+Na]
+ 443.2773, found 
443.2773 
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5-Prenyl-2,2-trimethyl-6-(1-methyl-2-oxopropyl)-1,3-Dioxin-4-one (4.1). LiN(SiMe3)2 
in THF (1 M; 0.22 mL, 0.22 mmol, 1 eq.) was added dropwise with stirring to 13.1 (46.8 
mg, 0.22 mmol, 1 eq.) in THF (1 mL) and the resulting pale yellow solution stirred at –70 
°C for 50 min, when AcCl (15 µL, 0.22 mmol, 1 eq.) was added. The reaction temperature 
was maintained at –70 °C for 45 min after which time the solution was poured onto aqueous 
HCl (1 M; 1 mL) and Et2O (2 mL) was added. The organic phase was washed with brine 
(3 × 5 mL), dried (MgSO4) and rotary evaporated. Chromatography (Et2O : Pentene 1:10 
to 1:5) gave product (4.1) (18.1 mg, 35%) as a colorless oil.  
 
1H NMR (400 MHz, CDCl3) δ 5.08 - 4.95 (m, 1H), 3.42 - 3.34 (s, 2H), 2.98 - 2.87 (d, J = 
6.8 Hz, 2H), 2.24 - 2.19 (s, 3H), 1.71 - 1.63 (s, 12H) 
 
 
 
5-Geranyl-2,2-trimethyl-6-(1-methyl-2-oxopropyl)-1,3-Dioxin-4-one (4.2). LiN(SiMe3)2 
in THF (1 M; 0.72 mL, 0.72 mmol, 1 eq.) was added dropwise with stirring to 13.2 (200 
mg, 0.72 mmol, 1 eq.) in THF (2.7 mL) and the resulting pale yellow solution stirred at –
70 °C for 1 h, when AcCl (51 µL, 0.72 mmol, 1 eq.) was added. The reaction temperature 
was maintained at –70 °C for 90 min after which time the solution was poured onto aqueous 
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HCl (1 M; 1 mL) and Et2O (2 mL) was added. The organic phase was washed with brine 
(3 × 5 mL), dried (MgSO4) and rotary evaporated. Chromatography (Et2O : Pentene 1 : 10 
to 1 : 5) gave keto-dioxinone (4.2) (18.1 mg, 32%) as a colorless oil.  
1H NMR (400 MHz, CDCl3) δ 5.10 – 4.99 (dddd, J = 9.6, 6.6, 4.7, 3.3 Hz, 2H), 3.43 – 3.34 
(s, 2H), 2.99 – 2.91 (d, J = 6.8 Hz, 2H), 2.24 – 2.19 (s, 3H), 2.12 – 1.90 (m, 4H), 1.74 – 
1.63 (d, J = 6.2 Hz, 12H), 1.57 – 1.53 (s, 3H).  13C NMR (126 MHz, CDCl3) δ 201.3, 162.0, 
159.3, 136.4, 131.5, 124.0, 121.1, 107.7, 105.6, 45.7, 39.5, 30.1, 29.7, 26.5, 25.7, 25.1, 
23.6, 17.7, 16.2. IR (film): ν = 2921, 2852, 1725, 1646, 1369 cm-1 HRMS [ES+] calc for 
C19H29O4 [M+H]
+ 321.2066, found 321.2063 
 
 
 
5-[10,11-Isopropylidenedioxy-10,11-dihydrofarnesyl]-2,2-trimethyl-6-(1-methyl-2-
oxopropyl)-1,3-Dioxin-4-one (4.3). LiN(SiMe3)2 in THF (1 M; 0.12 mL, 0.12 mmol, 1 
eq.) was added dropwise with stirring to 13.3 (50.2 g, 0.12 mmol, 1 eq.) in THF (1 mL) 
and the resulting pale yellow solution stirred at –70 °C for 50 min, when AcCl (8 µL, 0.12 
mmol, 1 eq.) was added. The reaction temperature was maintained at –70 °C for 45 min 
after which time the solution was poured onto aqueous HCl (1 M; 1 mL) and Et2O (2 mL) 
was added. The organic phase was washed with brine (3 × 5 mL), dried (MgSO4) and 
rotary evaporated. Chromatography (Et2O : Pentene 1:10 to 1:5) gave product (4.3) (18.1 
mg, 33%) as a colorless oil. 
1H NMR (400 MHz, CDCl3) δ 5.19 – 4.96 (m, 2H), 3.72 – 3.59 (dd, J = 9.3, 3.5 Hz, 1H), 
3.43 – 3.33 (s, 2H), 3.00 – 2.90 (d, J = 6.7 Hz, 2H), 2.25 – 2.20 (s, 3H), 2.18 – 1.93 (m, 
8H), 1.72 – 1.66 (d, J = 4.4 Hz, 9H), 1.63 – 1.59 (s, 3H), 1.45 – 1.40 (d, J = 2.2 Hz, 3H), 
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1.35 – 1.30 (s, 3H), 1.27 – 1.22 (d, J = 3.3 Hz, 3H), 1.11 – 1.07 (s, 3H). IR (film): ν = 2922, 
2852, 1729, 1373 cm-1 HRMS [ES+] calc for C27H42O6Na [M+Na]
+ 485.2879, found 
485.2880 
 
 
 
4-Hydroxy-6-methylpyran-2-one (16). A solution of Keto-dioxinone (14) (7 g, 38.8 mmol) 
in toluene (50 mL) was stirred at reflux for 2 h. The reaction mixture was allowed to warm 
to room temperature. The resulting precipitate formed was filtered off and washed with 
cold water, leading to the isolation of 4-hydroxy-6-methylpyran-2-one (16) as a white solid 
in 89% yield. 24 
1H NMR (400 MHz, CDCl3) δ 5.91 – 5.84 (d, J = 2.1 Hz, 1H), 5.52 – 5.43 (d, J = 2.0 Hz, 
1H), 2.30 – 2.21 (s, 3H) 
 
 
 
3-Acetyl-4-hydroxy-6-methyl-2-pyrone (20). To a solution of 3-Acetyl-4-hydroxy-6-
methyl-2-pyrone (16) (4.39 g, 34.8 mmol, 1 eq.) in toluene (85.0 mL), DMAP (0.85 g, 6.97 
mmol, 0.2 eq.), acetic acid (2 mL, 34.8 mmol), DCC (7.19 g, 34.8 mmol, 1 eq.) were added. 
The reaction mixture was stirred at 100 °C for 2 h, then the organic solution was 
evaporated. The crude product was purified by using column chromatography 
(Pentene:EtOAc 2:1) to afford 3.33 g of product 20 as light yellow solid. Yield: 56%. 3-
Methylcarbonyl-4-hydroxy-6-methyl-2-pyrone (20). 25 
1H NMR (400 MHz, CDCl3) δ 5.99 – 5.89 (s, 1H), 2.72 – 2.63 (s, 3H), 2.31 – 2.24 (s, 3H) 
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Methyl 3,5-diozohexanoate (17). To a magnetically stirred solution of magnesium 
methylate [prepared from Mg turnings (484 mg, 19.9 mmol) and MeOH (30.0 mL)] were 
added 3-Acetyl-4-hydroxy-6-methyl-2-pyrone (20) (1.11 g, 6.60 mmol, 3 eq.) and MeOH 
(30 mL). The reaction mixture was heated under reflux for 15 h and the solvent evaporated 
under reduced pressure. The residue was dissolved in AcOEt and acidified with 1N HCl 
(10 mL). After extracting with AcOEt (5 x 20 mL), the combined organic solution was 
washed with brine, dried (MgSO4) and evaporated. Chromatography (EtOAc : Pentene  1:2 
to 2:1) gave Methyl 3,5-diozohexanoate (17) (272 mg, 26%) as a colorless liquid.  
1H NMR (CDCI3, 200 MHz) : enol form: 
1H NMR (400 MHz, CDCl3) δ 5.62 – 5.59 (s, 
1H), 3.76 – 3.72 (d, J = 3.0 Hz, 3H), 3.36 – 3.31 (s, 2H), 2.11 – 2.06 (s, 3H) 
 
 
 
Bis-(Methy1 3,5-dioxohexanoate)-copper(II) (21). A solution of copper (II) acetate 
monohydrate (171 mg, 0.94 mmol) in water (2.7 mL) was added into a stirred solution of  
Methyl 3,5-diozohexanoate (17) (272 mg, 1.72 mmol, 1.8 eq.) in methanol (0.3 mL). The 
immediately formed precipitate was filtered, sequentially washed with water and with cold 
acetone and dried under vacum to afford 120 mg (31%) of Bis(Methy1 3,5-
dioxohexanoate)copper(II) (21). IR (thin film): 1731, 1631 cm-1. 
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10,11-Epoxyfarnesol (23). To a solution of 10,11-Epoxyfarnesyl acetate (500 mg, 1.78 
mmol) in 10 mL of methanol was added potassium carbonate (1.85 g, 13.4 mmol, 7.5 eq.), 
and the mixture was stirred at room temperature for 15 min. Water (20 mL) was added to 
the reaction mixture, and the aqueous layer was extracted with dichloromethane (20 mL × 
3). The organic solution was washed with brine, dried over anhydrous magnesium sulfate, 
and concentrated under reduced pressure. The Epoxyfarnesol (23) (443 mg, 99% yield) 
was pure enough to use in the next step. 26 
1H NMR (400 MHz, CDCl3) δ 5.49 – 5.35 (tt, J = 5.9, 1.4 Hz, 1H), 5.22 – 5.11 (tt, J = 5.4, 
1.6 Hz, 1H), 4.22 – 4.06 (dd, J = 6.9, 3.8 Hz, 2H), 2.76 – 2.63 (t, J = 6.1 Hz, 1H), 2.28 – 
1.95 (m, 8H), 1.74 – 1.50 (m, 6H), 1.37 – 1.28 (s, 3H), 1.28 – 1.23 (s, 3H) 
 
 
 
10,11-Epoxyfarnesyl bromide (24). To a solution of the allylic alcohol (23) (443 mg, 1.86 
mmol) and Et3N (0.52 mL, 3.72 mmol, 2 eq.) in 11 mL of dry THF, was added MsCl (0.19 
mL, 2.4 mmol, 1.3 eq) at -45 °C under Ar. After the mixture was stirred at this temperature 
for 45 min and then at 0 °C for 30 min, a solution of LiBr (2 M in THF, 4.7 mL, 9.3 mmol, 
5 eq.) was added and stirring was continued at 0°C for 1 h. The reaction mixture was the 
poured into a mixture of pentene (15 mL) and ice-cooled NaHCO3 (15 mL). The organic 
solution was separated and the aqueous layer was extracted twice with 15 mL of pentene. 
The combined organic phase was washed with brine and dried (MgSO4). After removal of 
the solvent, 461 mg (82%) of allylic bromide (24) was obtained as a colorless oil, which is 
pure enough for the following reaction. 
 
1H NMR (400 MHz, CDCl3) δ 5.62 – 5.45 (t, J = 8.5 Hz, 1H), 5.20 – 5.07 (t, J = 6.3 Hz, 
1H), 4.07 – 3.96 (d, J = 8.5 Hz, 2H), 2.77 – 2.65 (t, J = 6.1 Hz, 1H), 2.27 – 1.96 (dtt, J = 
15.8, 9.8, 5.6 Hz, 8H), 1.76 – 1.70 (s, 3H), 1.67 – 1.53 (m, 3H), 1.35 – 1.28 (s, 3H), 1.28 
– 1.23 (s, 3H)
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(2E,6E)-Farnesyl Acetate (8) 1H NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
 
(R,2E,6E)-10,11-Dihydroxy-3,7,11-trimethyldodeca-2,6-dienyl Acetate (9) 1H NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
Acetonide (10) 1H NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
32 
 
Alcohol (11) 1H NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33 
 
(10R)-10,11-Isopropylidenedioxy-10,11-dihydrofarnesyl bromide (6) 1H NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
5-iodo-1,3-dioxin-4-one (5) 1H NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
35 
 
5-Prenyl-2,2,6-trimethyl-[1,3]dioxin-4-one (13.1) 1H NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
5-Geranyl-2,2,6-trimethyl-[1,3]dioxin-4-one (13.2) 1H NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
37 
 
5-Geranyl-2,2,6-trimethyl-[1,3]dioxin-4-one (13.2) 13C  NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 
5-[10,11-Isopropylidenedioxy-10,11-dihydrofarnesyl]-2,2,6-trimethyl-[1,3]dioxin-4-one 
(13.3) 1H NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
39 
 
5-[10,11-Isopropylidenedioxy-10,11-dihydrofarnesyl]-2,2,6-trimethyl-[1,3]dioxin-4-one 
(13.3) 13C  NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
40 
 
5-Prenyl-2,2-trimethyl-6-(1-methyl-2-oxopropyl)-1,3-Dioxin-4-one (4.1) 1H NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
41 
 
5-Geranyl-2,2-trimethyl-6-(1-methyl-2-oxopropyl)-1,3-Dioxin-4-one (4.2) 1H NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
42 
 
5-Geranyl-2,2-trimethyl-6-(1-methyl-2-oxopropyl)-1,3-Dioxin-4-one (4.2) 13C  NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
43 
 
5-[10,11-Isopropylidenedioxy-10,11-dihydrofarnesyl]-2,2-trimethyl-6-(1-methyl-2-
oxopropyl)-1,3-Dioxin-4-one (4.3) 1H NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
5-[10,11-Isopropylidenedioxy-10,11-dihydrofarnesyl]-2,2-trimethyl-6-(1-methyl-2-
oxopropyl)-1,3-Dioxin-4-one (4.3) 13C  NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
4-Hydroxy-6-methylpyran-2-one (16) 1H NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
3-Acetyl-4-hydroxy-6-methyl-2-pyrone (20) 1H NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
47 
 
Methyl 3,5-diozohexanoate (17) 1H NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
48 
 
10,11-Epoxyfarnesol (23) 1H NMR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
 
10,11-Epoxyfarnesyl bromide (24) 1H NMR 
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